Bulking Agents (Microcystalline Cellulose, Dicalcium Phosphate), L-Glutathione, Anti-caking Agents (Silicon Dioxide, Magnesium Stearate), Biotin, Copper Sulphate.
They enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite via central hypothalamic pathways, leading to lower energy intake and improved glycemic control
The approval for the drug, which will be sold under the brand name Foundayo, marks an important technological inflection point for this class of drugs that is transforming obesity care in the US and around the world
Conclusion: A model using clinical and imaging data can accurately predict absence of high-risk varices in patients with HCC and avoid EGD in many patients prior to initiation of systemic therapy, thereby expediting care for patients with unresectable HCC